Extended safety check for liver disease drug shows ongoing monitoring for rare conditions
Disease control
Completed
This study monitored the long-term safety of maralixibat, a medication for rare cholestatic liver diseases like Alagille Syndrome. It included 52 patients who had already taken the drug in previous clinical trials and continued treatment. Researchers tracked side effects and look…
Phase: PHASE2 • Sponsor: Mirum Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC